Skip to main content
TipRanks
Go Ultimate75% OFF

Cardiol Therapeutics (CT9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

CT9 Analyst Ratings

Strong Buy
3Ratings
3Buy0Hold0Sell
Based on 3 analysts giving stock ratings to Cardiol Therapeutics in the past 3 months

CT9 Stock 12 Month Forecast

EUR 8.92▲(829.22% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is EUR 8.92 with a high forecast of EUR 9.81 and a low forecast of EUR 8.03. The average price target represents a 829.22% change from the last price of EUR 0.96.
Highest Price TargetEUR 9.81Average Price TargetEUR 8.92Lowest Price TargetEUR 8.03

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:CT9
Price TargetArticle
Canaccord GenuityEUR 8.92buy829.22%UpsideReiterated10/28/26
H.C. WainwrightEUR 8.03buy736.30%UpsideReiterated09/21/26
B. Riley SecuritiesEUR 9.81buy922.14%UpsideInitiated08/26/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HELPHelus Pharma
IMUXImmunic
CABACabaletta Bio
MDWDMediwound
OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cardiol Therapeutics

3 Months
Edward Nash
Edward NashCanaccord Genuity
Success Rate9/23 ratings generated profit
39%
Average Return
-0.48%

Copying Edward Nash's trades and holding each position for 3 Months would result in 39.13% of your transactions generating a profit, with an average return of -0.48% per trade.

1 Year
Edward Nash
Edward NashCanaccord Genuity
Success Rate7/23 ratings generated profit
30%
Average Return
+0.37%

Copying Edward Nash's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of +0.37% per trade.

2 Years
Edward Nash
Edward NashCanaccord Genuity
Success Rate3/23 ratings generated profit
13%
Average Return
-8.63%

Copying Edward Nash's trades and holding each position for 2 Years would result in 13.04% of your transactions generating a profit, with an average return of -8.63% per trade.

CT9 Analyst Recommendation Trends

02468Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
Monthly rating counts for CT9
RatingJun 26Jul 26Aug 26Sep 26Oct 26
Strong Buy55784
Buy00000
Hold00000
Sell00000
Strong Sell00000
total55784

In the current month, CT9 has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CT9 average Analyst price target in the past 3 months is 8.92.

CT9 Financial Forecast

EUR -2EUR -1.5EUR -1EUR -0.5EUR 0Q3 2025Q2 2026Q3 2026
HighEUR -0.04
ConsensusEUR -0.05
LowEUR -0.07

CT9 Earnings Forecast

Next quarter’s earnings estimate for CT9 is -EUR 0.05 with a range of -EUR 0.07 to -EUR 0.04. The previous quarter’s EPS was -EUR 0.03. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

EUR -1EUR -0.5EUR 0EUR 0.5EUR 1Q3 2025Q2 2026Q3 2026
HighEUR 0.00
ConsensusEUR 0.00
LowEUR 0.00

CT9 Sales Forecast

Next quarter’s sales forecast for CT9 is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

CT9 Stock Forecast FAQ

What is DE:CT9’s average 12-month price target, according to analysts?
Based on analyst ratings, Cardiol Therapeutics’s 12-month average price target is €8.92.
What is DE:CT9’s upside potential, based on the analysts’ average price target?
Cardiol Therapeutics has 829.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Cardiol Therapeutics a Buy, Sell or Hold?
Cardiol Therapeutics has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Cardiol Therapeutics’s share price target?
The average share price target for Cardiol Therapeutics is €8.92. This is based on 3 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €9.81, and the lowest forecast is €8.03. The average share price target represents a 829.22% increase from the current price of €0.96.
What do analysts say about Cardiol Therapeutics?
Cardiol Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of Cardiol Therapeutics?
To buy shares of DE:CT9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.